Tag: O’Melveny

Luzhu Biotechnology debuted on the HKEX through chapter 18A, the first biotech company without any revenue or profits to be listed this year, raising USD43.45 million

Morrison Foerster has expanded its private equity and M&A operation in China with the hiring of partner Zhao Rongjing from Kirkland & Ellis

O’Melveny advised China’s medical technology company, Acotec Scientific Holdings, on the voluntary partial offer for a majority stake of up to 65% by US-listed Boston Scientific Group

3D Medicines, an oncology medical research and development company, tapped Han Kun Law Firm’s intellectual property services during preparations for its HKD430 million Hong Kong IPO, to protect multiple patented drugs

Gaush Meditech, the fourth largest ophthalmic medical device company in China, raised HKD672 million (USD86.34 million) in its Hong Kong listing, offering a total of 13.06 million shares at HKD51.4 per share

China Business Law Journal reveals the law firms that have excelled in the past year